The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD

Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD

October 22, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—A biosimilar version of infliximab appears as effective as the original for treating pediatric inflammatory bowel disease (PIBD), and less costly, new research shows.

You Might Also Like
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • Infliximab Use Not Tied to Malignancy in Pediatric IBD
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

“These baseline data have now enabled us to confidently switch patients from originator to biosimilar, adopting the same prospective methodology to monitor effectiveness, safety and cost,” Dr. Lisa Richmond of the Royal Hospital for Children in Glasgow, U.K., and colleagues write in their Oct. 7 online report in the Archives of Disease in Childhood.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The European Medicines Agency approved the use of biosimilar infliximab in PIBD in 2015, but initial studies showing biosimilarity had been done in adults with rheumatic disease.

Dr. Richmond and her team collected prospective data on 40 PIBD patients from two regional referral centers who started the infliximab biosimilar, Remsima. Twenty-nine had Crohn’s disease (CD), 11 had ulcerative colitis (UC). Napp Pharmaceuticals, which makes Remsima, helped fund the study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Twelve weeks after treatment initiation, patients showed significant clinical and biochemical improvements. Two patients developed positive antibodies, one of whom had an acute infusion reaction. This patient had previously been exposed to Remicade, and was switched to adalimumab.

Remsima was 38% less expensive per vial than Remicade. The researchers estimate that the 190 total infusions patients received cost about 47,800 British pounds (US$ 62,866) less.

“Recent guidelines have generally advised caution in the use of biosimilar anti-TNFs until further data on their use have become available,” Dr. Richmond and colleagues write. “We hope this study will help support their wider introduction into paediatric practice.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Richmond was not available for an interview by press time.


Reference

  1. Richmond L, Curtis L, Garrick V, et al. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2017 Oct 7. pii: archdischild-2017-313404. doi: 10.1136/archdischild-2017-313404. [Epub ahead of print]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, Crohn's disease, inflammatory bowel disease, infliximab, Pediatric, ulcerative colitis

You Might Also Like:
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • Infliximab Use Not Tied to Malignancy in Pediatric IBD
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)